Institute of Laboratory Medicine, Universities of Giessen and Marburg Lung Center (UGMLC), Philipps Universität Marburg, German Center for Lung Research (DZL) Marburg, Baldinger Straße, 35043 Marburg, Germany.
4th Department of Internal Medicine, Attikon University Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
J Infect. 2020 Aug;81(2):205-212. doi: 10.1016/j.jinf.2020.06.039. Epub 2020 Jun 21.
A subgroup of COVID-19 patients develop very severe disease with requirement for ICU treatment, ventilation, and ECMO therapy. Laboratory tests indicate that the immune and clotting system show marked alterations with hyper-activation, hyper-inflammation, cytokine storm development. Furthermore, organ-specific biomarkers demonstrate the involvement of cardiac muscle, kidney, and liver dysfunction in many patients. In this article the use of laboratory biomarkers is discussed with regard to their use for diagnosis, disease progression, and risk assessment.
一小部分 COVID-19 患者病情发展非常严重,需要 ICU 治疗、通气和 ECMO 治疗。实验室检测表明,免疫和凝血系统出现明显改变,表现为过度激活、过度炎症、细胞因子风暴发展。此外,器官特异性生物标志物表明许多患者的心肌、肾脏和肝功能受损。本文讨论了实验室生物标志物的应用,包括用于诊断、疾病进展和风险评估。